glp-1 agonist prediabetes Receptor Agonists as Treatments for Type 2 Diabetes Comparing Ozempic, Wegovy and Other
Description
There are additional concerns
Patients should be counselled to expect these potential side-effects
2018;236(1):R29-R42
SUSTAIN-6 evaluated once-weekly semaglutide versus placebo in patients at moderate and high cardiovascular risk with type 2 diabetes, showing a 26% relative risk reduction in MACE (HR 0.74, 95% CI 0.58 to 0.95)
Supplements and complementary approaches Certain supplements can support GLP-1 therapy outcomes, potentially allowing patients to maintain results at lower medication doses
